Shopping Cart 0
Cart Subtotal
USD 0

Dr. Reddys Laboratories Ltd (DRREDDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company's generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, infectious diseases and pediatrics. The company provides more than 150 products. The company also develops generic biosimilar products and has four products in the market. The company also discovers, develops, manufactures and markets New Chemical Entities (NCEs) focusing on bacterial infections, metabolic disorders, pain and inflammation. The company markets products in over 75 countries in the US, Europe, Latin America and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.

Dr. Reddy's Laboratories Ltd (DRREDDY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Dr. Reddy's Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17

Dr. Reddy's Labs Acquires Six OTC Brands from Ducere Pharma 19

Dr. Reddy's Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20

Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 21

Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 22

Dr Reddy's Labs Plans To Acquire Drug Brands In Latin America 23

Private Equity 24

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24

Partnerships 26

Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 26

Department of Science & Technology Enters into Agreement with Dr Reddy's Labs, University of Hyderabad and Dr Reddy's Institute of Life Sciences 27

Dr. Reddy's Labs Enters into Co-Marketing Agreement with Gland Pharma 28

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29

CutisPharma Partners with Dr. Reddy's Labs 30

Dr. Reddy's Labs Enters into Agreement with TR-Pharm 31

Dr. Reddy's Labs Enters into Distribution Agreement with Biocodex 32

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 33

Purdue University Enters into MoU with Dr Reddy's Labs 34

Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 35

Dr Reddy's Labs Plans to Enter into Agreement 36

Aurigene Discovery Enters into Agreement with Curis 37

Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy's Laboratories 39

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40

Licensing Agreements 41

Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42

Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 43

Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 44

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45

Dr. Reddy's Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47

Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy's Labs 48

Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51

Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 52

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53

Dr. Reddy's Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54

Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55

Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56

Equity Offering 57

Octoplus Completes First Tranche Of Private Placement Of Common Stock For USD 1.6 Million 57

Asset Transactions 58

Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy's Laboratories 58

EPI Health Acquires Rights of Cloderm from Promius Pharma 59

Genomma Lab Acquires Bufferin Brand from Dr. Reddy's Labs 60

Acquisition 61

Neopharma Acquires Dr. Reddy's Laboratories Tennessee from Dr. Reddy's Laboratories 61

Dr Reddy's Labs Acquires OctoPlus 62

Dr. Reddy's Laboratories Ltd-Key Competitors 64

Dr. Reddy's Laboratories Ltd-Key Employees 65

Dr. Reddy's Laboratories Ltd-Locations And Subsidiaries 66

Head Office 66

Other Locations & Subsidiaries 66

Joint Venture 68

Recent Developments 69

Financial Announcements 69

Oct 26, 2018: Dr. Reddy's Q2 & H1 FY19 financial results 69

Jul 26, 2018: Dr. Reddy's Q1 FY19 financial results 70

May 22, 2018: Dr. Reddy's Q4 and FY18 Financial Results 72

Jan 25, 2018: Dr. Reddy's Q3 and 9M FY18 Financial Results 74

Oct 31, 2017: Dr. Reddy's Q2 and H1 FY18 Financial Results 76

Jul 27, 2017: Dr. Reddy's Q1 FY18 Financial Results 77

May 12, 2017: Dr. Reddy's Q4 and FY17 Financial Results 78

Feb 04, 2017: Dr. Reddy's Q3 and 9M FY17 Financial Results 80

Corporate Communications 82

Oct 25, 2018: Dr. Reddy's Laboratories: Appointment of Mr. Leo Puri as an Additional Director, categorjzed as Independent, on the Board of the Company 82

Jun 14, 2018: Dr. Reddy's Announces Resignation of Hans Peter Hasler As Independent Director 83

Mar 29, 2018: Dr. Reddy's Laboratories announces Senior Leadership Changes 84

Oct 30, 2017: Dr Reddys Laboratories appoints Prasad R Menon as an Additional Director 85

Legal and Regulatory 86

Oct 30, 2018: Dr Reddy's slips 7% following 8 USFDA observations for Duvvada plant 86

Aug 23, 2018: Dr. Reddy's Laboratories: Update on audit of API Srikakulam Plant, Andhra Pradesh 87

Jun 28, 2018: Dr. Reddy's Laboratories: Update on Audit of its API Hyderabad Plant 3 and API Hyderabad Plant 1 88

Jun 28, 2018: Indivior's Temporary Restraining Order is Extended 89

Jun 03, 2018: Dr Reddy's API Srikakulam plant gets USFDA nod 90

Jun 02, 2018: Dr. Reddy's Laboratories Provides Update on US FDA Inspection of its API Srikakulam Plant 91

Apr 24, 2018: Dr. Reddy's Laboratories Provides Update on US FDA Inspection of its API Plant in Mirfield, UK 92

Mar 16, 2018: Dr. Reddy's Provides Update on Update on USFDA Audit of its API Hyderabad Plant at Medak,Telangana 93

Feb 25, 2018: Dr. Reddy's Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India 94

Feb 19, 2018: Dr Reddy's Laboratories: Update on US Lawsuit 95

Jan 24, 2018: Dr. Reddy's Laboratories: Intimation regard to Communication from Betapharm Arzneimittel, Germany from the Regulatory Authority of Germany 96

Jan 22, 2018: Dr. Reddy's fined USD 5mn by US court over drug packaging 97

Dec 19, 2017: Dr. Reddy's announces it has reached a settlement with the US Government regarding company's compliance with the Consumer Product Safety Act 98

Dec 11, 2017: Dr. Reddys announced audit of formulations manufacturing plant 99

Dec 01, 2017: Dr. Reddy's Laboratories: Intimation regard to the US FDA audit 100

Nov 21, 2017: Dr. Reddy's Laboratories: Intimation regarding receipt of EIR 101

Sep 21, 2017: Dr. Reddys Announced audit of custom Pharmaceutical Services Facility 102

Sep 21, 2017: Dr. Reddy's Laboratories: Intimation about audit of Srikakulam Plant Unit II, Andhra Pradesh, by the US FDA 103

Sep 15, 2017: Dr. Reddy's Laboratories: Intimation about audit of API Mirfield Plant, United Kingdom, by the US FDA 104

Sep 08, 2017: Dr. Reddy's Laboratories: Regulatory Authority of Germany concludes audit of Formulations manufacturing facility in Vishakapatnam, India 105

Sep 08, 2017: Dr. Reddy's Laboratories Announces Intimation on audit 106

Jul 21, 2017: Dr. Reddy's Laboratories: Update On US FDA Audit at API Cuernavaca Plant 107

Jun 16, 2017: Dr. Reddy's Laboratories: Update on USFDA Audit 108

Jun 14, 2017: Dr. Reddy's Provides Update on API manufacturing plant at Miryalaguda 109

May 25, 2017: Dr. Reddy's Laboratories Provides Update on Srikakulum Plant 110

Apr 28, 2017: Dr. Reddy's Provides Update On US FDA Audit At Bachupally Plant 111

Apr 14, 2017: Dr. Reddy's Provides Update on USFDA Audit 112

Apr 03, 2017: Dr. Reddy's Laboratories Provides Update on USFDA Inspection at Srikakulam plant 113

Feb 21, 2017: Dr. Reddy's Laboratories Announces US FDA Inspection on Miryalaguda Facility 114

Product News 115

12/01/2017: Dr. Reddy's Announces Approval of Impoyz (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval 115

Aug 28, 2017: Dr. Reddy's Laboratories Breathes New Life into Doan's in New Marketing Campaign 116

Jun 03, 2018: Dr Reddy's expects to launch over 15 products in US in FY'19 117

Jan 17, 2018: Dr Reddy's recalls over 1,000 vials of cancer drug from US 118

Clinical Trials 119

Feb 07, 2018: Armis Biopharma to Present at the BIO CEO & Investor Conference 119

Jan 29, 2018: Armis Biopharma Granted QIDP for Lead Product, Ximycin for Prophylaxis of Surgical Site Infections in High-Risk Patients Undergoing Non-Emergent Colorectal Surgery 120

Other Significant Developments 121

Feb 08, 2017: Dr. Reddy's Expands Commercial Operations in Europe 121

Appendix 122

Methodology 122

About GlobalData 122

Contact Us 122

Disclaimer 122


List Of Figure

List of Figures

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Dr. Reddy's Laboratories Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Dr. Reddy's Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17

Dr. Reddy's Labs Acquires Six OTC Brands from Ducere Pharma 19

Dr. Reddy's Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20

Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 21

Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 22

Dr Reddy's Labs Plans To Acquire Drug Brands In Latin America 23

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24

Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 26

Department of Science & Technology Enters into Agreement with Dr Reddy's Labs, University of Hyderabad and Dr Reddy's Institute of Life Sciences 27

Dr. Reddy's Labs Enters into Co-Marketing Agreement with Gland Pharma 28

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29

CutisPharma Partners with Dr. Reddy's Labs 30

Dr. Reddy's Labs Enters into Agreement with TR-Pharm 31

Dr. Reddy's Labs Enters into Distribution Agreement with Biocodex 32

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 33

Purdue University Enters into MoU with Dr Reddy's Labs 34

Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 35

Dr Reddy's Labs Plans to Enter into Agreement 36

Aurigene Discovery Enters into Agreement with Curis 37

Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy's Laboratories 39

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40

Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42

Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 43

Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 44

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45

Dr. Reddy's Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47

Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy's Labs 48

Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51

Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 52

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53

Dr. Reddy's Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54

Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55

Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56

Octoplus Completes First Tranche Of Private Placement Of Common Stock For USD 1.6 Million 57

Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy's Laboratories 58

EPI Health Acquires Rights of Cloderm from Promius Pharma 59

Genomma Lab Acquires Bufferin Brand from Dr. Reddy's Labs 60

Neopharma Acquires Dr. Reddy's Laboratories Tennessee from Dr. Reddy's Laboratories 61

Dr Reddy's Labs Acquires OctoPlus 62

Dr. Reddy's Laboratories Ltd, Key Competitors 64

Dr. Reddy's Laboratories Ltd, Key Employees 65

Dr. Reddy's Laboratories Ltd, Subsidiaries 66

Dr. Reddy's Laboratories Ltd, Joint Venture 68

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Dr. Reddy's Laboratories Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company's generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, infectious diseases and pediatrics. The company provides more than 150 products. The company also develops generic biosimilar products and has four products in the market. The company also discovers, develops, manufactures and markets New Chemical Entities (NCEs) focusing on bacterial infections, metabolic disorders, pain and inflammation. The company markets products in over 75 countries in the US, Europe, Latin America and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.

Dr. Reddy's Laboratories Ltd (DRREDDY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Dr. Reddy's Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17

Dr. Reddy's Labs Acquires Six OTC Brands from Ducere Pharma 19

Dr. Reddy's Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20

Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 21

Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 22

Dr Reddy's Labs Plans To Acquire Drug Brands In Latin America 23

Private Equity 24

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24

Partnerships 26

Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 26

Department of Science & Technology Enters into Agreement with Dr Reddy's Labs, University of Hyderabad and Dr Reddy's Institute of Life Sciences 27

Dr. Reddy's Labs Enters into Co-Marketing Agreement with Gland Pharma 28

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29

CutisPharma Partners with Dr. Reddy's Labs 30

Dr. Reddy's Labs Enters into Agreement with TR-Pharm 31

Dr. Reddy's Labs Enters into Distribution Agreement with Biocodex 32

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 33

Purdue University Enters into MoU with Dr Reddy's Labs 34

Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 35

Dr Reddy's Labs Plans to Enter into Agreement 36

Aurigene Discovery Enters into Agreement with Curis 37

Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy's Laboratories 39

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40

Licensing Agreements 41

Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42

Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 43

Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 44

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45

Dr. Reddy's Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47

Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy's Labs 48

Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51

Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 52

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53

Dr. Reddy's Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54

Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55

Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56

Equity Offering 57

Octoplus Completes First Tranche Of Private Placement Of Common Stock For USD 1.6 Million 57

Asset Transactions 58

Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy's Laboratories 58

EPI Health Acquires Rights of Cloderm from Promius Pharma 59

Genomma Lab Acquires Bufferin Brand from Dr. Reddy's Labs 60

Acquisition 61

Neopharma Acquires Dr. Reddy's Laboratories Tennessee from Dr. Reddy's Laboratories 61

Dr Reddy's Labs Acquires OctoPlus 62

Dr. Reddy's Laboratories Ltd-Key Competitors 64

Dr. Reddy's Laboratories Ltd-Key Employees 65

Dr. Reddy's Laboratories Ltd-Locations And Subsidiaries 66

Head Office 66

Other Locations & Subsidiaries 66

Joint Venture 68

Recent Developments 69

Financial Announcements 69

Oct 26, 2018: Dr. Reddy's Q2 & H1 FY19 financial results 69

Jul 26, 2018: Dr. Reddy's Q1 FY19 financial results 70

May 22, 2018: Dr. Reddy's Q4 and FY18 Financial Results 72

Jan 25, 2018: Dr. Reddy's Q3 and 9M FY18 Financial Results 74

Oct 31, 2017: Dr. Reddy's Q2 and H1 FY18 Financial Results 76

Jul 27, 2017: Dr. Reddy's Q1 FY18 Financial Results 77

May 12, 2017: Dr. Reddy's Q4 and FY17 Financial Results 78

Feb 04, 2017: Dr. Reddy's Q3 and 9M FY17 Financial Results 80

Corporate Communications 82

Oct 25, 2018: Dr. Reddy's Laboratories: Appointment of Mr. Leo Puri as an Additional Director, categorjzed as Independent, on the Board of the Company 82

Jun 14, 2018: Dr. Reddy's Announces Resignation of Hans Peter Hasler As Independent Director 83

Mar 29, 2018: Dr. Reddy's Laboratories announces Senior Leadership Changes 84

Oct 30, 2017: Dr Reddys Laboratories appoints Prasad R Menon as an Additional Director 85

Legal and Regulatory 86

Oct 30, 2018: Dr Reddy's slips 7% following 8 USFDA observations for Duvvada plant 86

Aug 23, 2018: Dr. Reddy's Laboratories: Update on audit of API Srikakulam Plant, Andhra Pradesh 87

Jun 28, 2018: Dr. Reddy's Laboratories: Update on Audit of its API Hyderabad Plant 3 and API Hyderabad Plant 1 88

Jun 28, 2018: Indivior's Temporary Restraining Order is Extended 89

Jun 03, 2018: Dr Reddy's API Srikakulam plant gets USFDA nod 90

Jun 02, 2018: Dr. Reddy's Laboratories Provides Update on US FDA Inspection of its API Srikakulam Plant 91

Apr 24, 2018: Dr. Reddy's Laboratories Provides Update on US FDA Inspection of its API Plant in Mirfield, UK 92

Mar 16, 2018: Dr. Reddy's Provides Update on Update on USFDA Audit of its API Hyderabad Plant at Medak,Telangana 93

Feb 25, 2018: Dr. Reddy's Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India 94

Feb 19, 2018: Dr Reddy's Laboratories: Update on US Lawsuit 95

Jan 24, 2018: Dr. Reddy's Laboratories: Intimation regard to Communication from Betapharm Arzneimittel, Germany from the Regulatory Authority of Germany 96

Jan 22, 2018: Dr. Reddy's fined USD 5mn by US court over drug packaging 97

Dec 19, 2017: Dr. Reddy's announces it has reached a settlement with the US Government regarding company's compliance with the Consumer Product Safety Act 98

Dec 11, 2017: Dr. Reddys announced audit of formulations manufacturing plant 99

Dec 01, 2017: Dr. Reddy's Laboratories: Intimation regard to the US FDA audit 100

Nov 21, 2017: Dr. Reddy's Laboratories: Intimation regarding receipt of EIR 101

Sep 21, 2017: Dr. Reddys Announced audit of custom Pharmaceutical Services Facility 102

Sep 21, 2017: Dr. Reddy's Laboratories: Intimation about audit of Srikakulam Plant Unit II, Andhra Pradesh, by the US FDA 103

Sep 15, 2017: Dr. Reddy's Laboratories: Intimation about audit of API Mirfield Plant, United Kingdom, by the US FDA 104

Sep 08, 2017: Dr. Reddy's Laboratories: Regulatory Authority of Germany concludes audit of Formulations manufacturing facility in Vishakapatnam, India 105

Sep 08, 2017: Dr. Reddy's Laboratories Announces Intimation on audit 106

Jul 21, 2017: Dr. Reddy's Laboratories: Update On US FDA Audit at API Cuernavaca Plant 107

Jun 16, 2017: Dr. Reddy's Laboratories: Update on USFDA Audit 108

Jun 14, 2017: Dr. Reddy's Provides Update on API manufacturing plant at Miryalaguda 109

May 25, 2017: Dr. Reddy's Laboratories Provides Update on Srikakulum Plant 110

Apr 28, 2017: Dr. Reddy's Provides Update On US FDA Audit At Bachupally Plant 111

Apr 14, 2017: Dr. Reddy's Provides Update on USFDA Audit 112

Apr 03, 2017: Dr. Reddy's Laboratories Provides Update on USFDA Inspection at Srikakulam plant 113

Feb 21, 2017: Dr. Reddy's Laboratories Announces US FDA Inspection on Miryalaguda Facility 114

Product News 115

12/01/2017: Dr. Reddy's Announces Approval of Impoyz (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval 115

Aug 28, 2017: Dr. Reddy's Laboratories Breathes New Life into Doan's in New Marketing Campaign 116

Jun 03, 2018: Dr Reddy's expects to launch over 15 products in US in FY'19 117

Jan 17, 2018: Dr Reddy's recalls over 1,000 vials of cancer drug from US 118

Clinical Trials 119

Feb 07, 2018: Armis Biopharma to Present at the BIO CEO & Investor Conference 119

Jan 29, 2018: Armis Biopharma Granted QIDP for Lead Product, Ximycin for Prophylaxis of Surgical Site Infections in High-Risk Patients Undergoing Non-Emergent Colorectal Surgery 120

Other Significant Developments 121

Feb 08, 2017: Dr. Reddy's Expands Commercial Operations in Europe 121

Appendix 122

Methodology 122

About GlobalData 122

Contact Us 122

Disclaimer 122


List Of Figure

List of Figures

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Dr. Reddy's Laboratories Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Dr. Reddy's Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17

Dr. Reddy's Labs Acquires Six OTC Brands from Ducere Pharma 19

Dr. Reddy's Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20

Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 21

Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 22

Dr Reddy's Labs Plans To Acquire Drug Brands In Latin America 23

Cipla, Zydus Cadilla, Dr. Reddy's Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24

Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 26

Department of Science & Technology Enters into Agreement with Dr Reddy's Labs, University of Hyderabad and Dr Reddy's Institute of Life Sciences 27

Dr. Reddy's Labs Enters into Co-Marketing Agreement with Gland Pharma 28

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29

CutisPharma Partners with Dr. Reddy's Labs 30

Dr. Reddy's Labs Enters into Agreement with TR-Pharm 31

Dr. Reddy's Labs Enters into Distribution Agreement with Biocodex 32

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 33

Purdue University Enters into MoU with Dr Reddy's Labs 34

Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 35

Dr Reddy's Labs Plans to Enter into Agreement 36

Aurigene Discovery Enters into Agreement with Curis 37

Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy's Laboratories 39

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40

Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42

Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 43

Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 44

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45

Dr. Reddy's Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47

Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy's Labs 48

Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49

Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50

Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51

Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 52

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53

Dr. Reddy's Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54

Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55

Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56

Octoplus Completes First Tranche Of Private Placement Of Common Stock For USD 1.6 Million 57

Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy's Laboratories 58

EPI Health Acquires Rights of Cloderm from Promius Pharma 59

Genomma Lab Acquires Bufferin Brand from Dr. Reddy's Labs 60

Neopharma Acquires Dr. Reddy's Laboratories Tennessee from Dr. Reddy's Laboratories 61

Dr Reddy's Labs Acquires OctoPlus 62

Dr. Reddy's Laboratories Ltd, Key Competitors 64

Dr. Reddy's Laboratories Ltd, Key Employees 65

Dr. Reddy's Laboratories Ltd, Subsidiaries 66

Dr. Reddy's Laboratories Ltd, Joint Venture 68

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Dr. Reddy's Laboratories Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.